In other words, the average US selling price after discounts and rebates declined relative to prior quarters.
It would be of more interest if Teva broke out their unit volume because I can't see pricing leading to the negative numbers. I wouldn't think Teva's renegotiation would negate a 14.9% price increase on Jan 3rd, 2012.